Iron Therapy in Cancer‑Related Anemia: Evidence‑Based Guidance
1. Efficacy of Intravenous Iron
2. Definitions of Iron Deficiency in Oncology
3. Clinical Benefits of Iron Supplementation
4. Caution in Liver Disease
5. Preference for Intravenous Formulations
6. Monitoring and Safety Measures
7. Recognizing Functional Iron Deficiency
8. Evaluation of Anemia Etiology (Supporting Evidence)
Indications for Intravenous Iron Therapy
Primary Indications
- The National Comprehensive Cancer Network recommends IV iron monotherapy for cancer patients with absolute iron deficiency (ferritin <30 ng/mL, TSAT <15%) 6, 7
- The National Comprehensive Cancer Network recommends IV iron combined with erythropoiesis-stimulating agents (ESAs) for cancer patients with functional iron deficiency (ferritin ≤800 ng/mL, TSAT <20%) during chemotherapy 6, 7, 8
Condition-Specific Indications
- The National Comprehensive Cancer Network recommends against administering IV iron during active infection or neutropenia due to risk of bacterial growth 7, 9, 10
- The American Journal of Hematology suggests avoiding IV iron on the same day as anthracyclines due to theoretical cardiotoxicity risk 11
Practical Administration Guidelines
- The National Comprehensive Cancer Network recommends choosing high-dose formulations allowing complete repletion in 1-2 infusions (ferric carboxymaltose or iron isomaltoside) 12
- The National Comprehensive Cancer Network recommends avoiding high-molecular-weight iron dextran (Dexferrum) due to increased anaphylaxis risk 7, 9, 10
Safety Monitoring
- Praxis Medical Insights recommends managing infusion reactions by temporarily stopping and restarting at slower rate 12
- Praxis Medical Insights recommends avoiding diphenhydramine for infusion reactions as side effects can mimic worsening reaction 12
Critical Contraindications
- The National Comprehensive Cancer Network recommends against using IV iron in patients with active infection (theoretical risk of promoting bacterial growth) 7, 9, 10
- The American Journal of Hematology recommends against using IV iron in cancer patients with neutropenia 11
- The National Comprehensive Cancer Network recommends against using IV iron in patients with iron overload (ferritin >800 ng/mL and TSAT >50% in cancer patients) 6, 7, 11